investor center media global distributors contact us ordering purchase products Products & Services Science Development Company Development Patents The majority of our gene rearrangement and gene mutation testing products are covered by patents owned by or exclusively licensed to Invivoscribe Technologies, Inc. Click here to inquire about sublicensing opportunities. in vivo cDNA synthesis technologies Invivoscribe holds exclusive rights to the following patent: United States Patent Number 6,498,025 Managing biomarkers and associated licenses Invivoscribe has exclusive rights to the following patent application: United States Provisional Patent Application 61/473,716 Method for analysing a marker nucleic acid molecule Invivoscribe Technologies holds exclusive rights to the following patent and patent applications that cover a method of analysing a rearranged immunoglobulin or T cell receptor variable region gene: United States Patent Number 7,785,783 International Patent Application PCT/AU2004/000625 Brazil Patent Application Number PI0410283.5 Canadian Patent Application Number 2525122 European Patent Application Number 04732551.9 Indian Patent Application Number 5792/DELNP/2005 Japanese Patent Application Number 2006-529437 Mexican Patent Application Number PA/a/2005/012102 Chinese Patent Application Number 200480016603.5 Korean Patent Application Number 10-2005-7021561 Determining the replicative history of lymphocytes Invivoscribe Technologies holds exclusive rights to the following patent and patent applications: United States Patent Application 20070003951 United States Patent Application 11/409,718 A method for DNA breakpoint analysis Invivoscribe Technologies holds exclusive rights to the following patent applications: United States Patent Application 20090202999 United States Patent Application 20100216138 International Patent Application Number PCT/AU2008/000779 A method for DNA amplification Invivoscribe Technologies holds exclusive rights to the following patent applications: International Patent Application 02/10/2008 International Patent Application PCT/AU2008/001453 United States Patent Application 20100248310 A method for amplification Invivoscribe Technologies holds exclusive rights to the following patent applications: United States Provisional Patent Application 61/217707 United States Patent Application 20100304444 Detecting targets using nucleic acids having both a variable region and a conserved region Invivoscribe Technologies holds exclusive rights to the following patent application: United States Patent Application 20090209432 Method of regulating oligonucleotide functionality Invivoscribe Technologies holds exclusive rights to the following patent application: United States Provisional Patent Application 61/319146 Nucleic acid amplification primers for PCR-based clonality studies of the TCR-Beta Gene Invivoscribe holds the exclusive license to intellectual property covering methods and compositions developed by the BIOMED-2/EuroClonality Group, with the right to use and apply methods and the right to manufacture, market, offer for sale and sell products in affiliation with the BIOMED-2/EuroClonality Group. Further, the license limits affiliation of BIOMED-2/EuroClonality Group to Invivoscribe only and allows Invivoscribe to use the name of the BIOMED-2/EuroClonality Group in marketing and sales materials. Granted European Patent and divisionals of underlying application 10185191.3 (applicable in 25 EU countries) Nucleic acid amplification primers for PCR-based clonality studies Invivoscribe holds the exclusive license to intellectual property covering methods and compositions developed by the BIOMED-2/EuroClonality Group, with the right to use and apply methods and the right to manufacture, market, offer for sale and sell products in affiliation with the BIOMED-2/EuroClonality Group. Further, the license limits affiliation of BIOMED-2/EuroClonality Group to Invivoscribe only and allows Invivoscribe to use the name of the BIOMED-2/EuroClonality Group in marketing and sales materials. Granted European Patent and divisionals of underlying application 10185204.4 (applicable in 25 EU countries) Granted European Patent Number EP 1549764B1, and divisionals of underlying application 03756746.8 (applicable in 16 EU countries) Granted Japanese Patent Number P04708029B2 United States Patent Application 10/531,106 Nucleic acid encoding receptor type protein kinase, FLT3 Invivoscribe Technologies holds the exclusive license (ex-Japan, discussed below) to develop, manufacture, use, and sell testing reagents for FLT3/ITD mutation detection. We hold rights to granted patents in the U.S. and in Europe and are both prosecuting existing patent applications and preparing a number of additional patent applications covering this technology to ensure that we maximize the breadth of claims and solidify our already comprehensive IP coverage. Issued patents and patent applications currently pending that are licensed exclusively to IVS include: United States Patent Number 6,846,630 United States Patent Number 8,178,292 Granted European Patent Number 0959132 (validated in 16 EU countries) United States Patent Application 12/938,617 United States Patent Application 12/938,629 United States Patent Application 12/938,723 United States Patent Application 12/938,712 United States Patent Application 12/557,193 Invivoscribe also holds a sole license (as to some reagent classes) and an exclusive license (as to other reagents) to develop, manufacture and sell testing reagents for use in Japan, under Japan Patent Number 3607704. Nucleophosmin protein (NPM1) mutants, corresponding gene sequences and uses thereof Invivoscribe holds rights to use technologies related to the following patent applications: Canadian Patent Application 2585965 United States Patent Application 11/666,542 European Patent Application EP20050813231 Chinese Patent Application 200580045036.0 BIOMARKERS Biomarkers are used to tailor treatments for the disease in an individual. Which Biomarkers should you be tested for if you have been diagnosed with Leukemia, Lymphoma or a Lymphoproliferative disease? Learn more privacy policy terms & conditions code of conduct © 2014 Invivoscribe